Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity

seekingalpha.com/article/4785451-iovance-biotherapeutics-stock-abysmal-q1-2025-performance-creates-buying-opportunity

Summary
- Iovance Biotherapeutics' stock plummeted 45% after a Q1 earnings miss, driven by temporary manufacturing issues and reduced revenue guidance.
- Management expects a rebound in Q2 with resumed full manufacturing capacity and increased commercial infusions, potentially leading to…

This story appeared on seekingalpha.com, 2025-05-12 05:28:01.
The Entire Business World on a Single Page. Free to Use →